Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus

R. S. Klein, Peter A. Selwyn, D. Maude, C. Pollard, K. Freeman, G. Schiffman

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Antibody responses to pneumococcal vaccine were studied in asymptomatic heterosexual partners of persons with AIDS and intravenous drug users seropositive for human immunodeficiency virus (HIV). Serum antibodies to 12 pneumococcal capsular antigens were measured by radioimmunoassay. Eleven intravenous drug users seropositive for HIV, 13 seronegative intravenous drug users, and 10 each seropositive and seronegative sexual partners received 23-valent pneumococcal vaccine. Additional unvaccinated matched seropositives served as controls. Antibody responses were significantly lower among subjects seropositive for HIV (P < .05). Fourteen (88%) of 16 seropositive subjects with baseline type-specific antibodies to one or more pneumococcal antigen < 300 ng of antibody nitrogen/ml (ngAbN/ml) demonstrated a rise in one or more of these antibodies to > 400 ngAbN/ml. No clinical deterioration or decrease in T4 cells attributable to vaccination was found. Although antibody responses to pneumococcal vaccine among HIV-infected subjects were impaired, most with antibody levels < 300 ngAbN/ml developed titers of one or more type-specific antibodies to levels > 400 ngAbN/ml without notable adverse effects.

Original languageEnglish (US)
Pages (from-to)826-831
Number of pages6
JournalJournal of Infectious Diseases
Volume160
Issue number5
StatePublished - 1989

Fingerprint

Anti-HIV Agents
Pneumococcal Vaccines
Heterosexuality
Drug Users
HIV
Antibody Formation
CD4-Positive T-Lymphocytes
Antibodies
Sexual Partners
Radioimmunoassay
Vaccination
Antigens
Serum

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus. / Klein, R. S.; Selwyn, Peter A.; Maude, D.; Pollard, C.; Freeman, K.; Schiffman, G.

In: Journal of Infectious Diseases, Vol. 160, No. 5, 1989, p. 826-831.

Research output: Contribution to journalArticle

@article{19963d1fc55341189c201e3c0674e035,
title = "Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus",
abstract = "Antibody responses to pneumococcal vaccine were studied in asymptomatic heterosexual partners of persons with AIDS and intravenous drug users seropositive for human immunodeficiency virus (HIV). Serum antibodies to 12 pneumococcal capsular antigens were measured by radioimmunoassay. Eleven intravenous drug users seropositive for HIV, 13 seronegative intravenous drug users, and 10 each seropositive and seronegative sexual partners received 23-valent pneumococcal vaccine. Additional unvaccinated matched seropositives served as controls. Antibody responses were significantly lower among subjects seropositive for HIV (P < .05). Fourteen (88{\%}) of 16 seropositive subjects with baseline type-specific antibodies to one or more pneumococcal antigen < 300 ng of antibody nitrogen/ml (ngAbN/ml) demonstrated a rise in one or more of these antibodies to > 400 ngAbN/ml. No clinical deterioration or decrease in T4 cells attributable to vaccination was found. Although antibody responses to pneumococcal vaccine among HIV-infected subjects were impaired, most with antibody levels < 300 ngAbN/ml developed titers of one or more type-specific antibodies to levels > 400 ngAbN/ml without notable adverse effects.",
author = "Klein, {R. S.} and Selwyn, {Peter A.} and D. Maude and C. Pollard and K. Freeman and G. Schiffman",
year = "1989",
language = "English (US)",
volume = "160",
pages = "826--831",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus

AU - Klein, R. S.

AU - Selwyn, Peter A.

AU - Maude, D.

AU - Pollard, C.

AU - Freeman, K.

AU - Schiffman, G.

PY - 1989

Y1 - 1989

N2 - Antibody responses to pneumococcal vaccine were studied in asymptomatic heterosexual partners of persons with AIDS and intravenous drug users seropositive for human immunodeficiency virus (HIV). Serum antibodies to 12 pneumococcal capsular antigens were measured by radioimmunoassay. Eleven intravenous drug users seropositive for HIV, 13 seronegative intravenous drug users, and 10 each seropositive and seronegative sexual partners received 23-valent pneumococcal vaccine. Additional unvaccinated matched seropositives served as controls. Antibody responses were significantly lower among subjects seropositive for HIV (P < .05). Fourteen (88%) of 16 seropositive subjects with baseline type-specific antibodies to one or more pneumococcal antigen < 300 ng of antibody nitrogen/ml (ngAbN/ml) demonstrated a rise in one or more of these antibodies to > 400 ngAbN/ml. No clinical deterioration or decrease in T4 cells attributable to vaccination was found. Although antibody responses to pneumococcal vaccine among HIV-infected subjects were impaired, most with antibody levels < 300 ngAbN/ml developed titers of one or more type-specific antibodies to levels > 400 ngAbN/ml without notable adverse effects.

AB - Antibody responses to pneumococcal vaccine were studied in asymptomatic heterosexual partners of persons with AIDS and intravenous drug users seropositive for human immunodeficiency virus (HIV). Serum antibodies to 12 pneumococcal capsular antigens were measured by radioimmunoassay. Eleven intravenous drug users seropositive for HIV, 13 seronegative intravenous drug users, and 10 each seropositive and seronegative sexual partners received 23-valent pneumococcal vaccine. Additional unvaccinated matched seropositives served as controls. Antibody responses were significantly lower among subjects seropositive for HIV (P < .05). Fourteen (88%) of 16 seropositive subjects with baseline type-specific antibodies to one or more pneumococcal antigen < 300 ng of antibody nitrogen/ml (ngAbN/ml) demonstrated a rise in one or more of these antibodies to > 400 ngAbN/ml. No clinical deterioration or decrease in T4 cells attributable to vaccination was found. Although antibody responses to pneumococcal vaccine among HIV-infected subjects were impaired, most with antibody levels < 300 ngAbN/ml developed titers of one or more type-specific antibodies to levels > 400 ngAbN/ml without notable adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0024416914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024416914&partnerID=8YFLogxK

M3 - Article

C2 - 2572650

AN - SCOPUS:0024416914

VL - 160

SP - 826

EP - 831

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -